For Research Purposes Only

Dosing Protocol

AOD-9604 Dosing Protocol

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) studied specifically for fat metabolism without the proliferative or diabetogenic effects of full-length GH. It has TGA approval in Australia as an oral supplement ingredient.

Key Points

Dose: 300-500 mcg/day subcutaneously, fasted
GH fragment without diabetogenic or proliferative effects
TGA-approved in Australia as supplement ingredient
12-20 week protocols for assessment
Modest fat loss effects compared to GLP-1 agonists

Step-by-Step Guide

1

Set Standard Dose

Research protocols use 300-500 mcg/day subcutaneously. Some studies used oral doses of 1 mg/day, though oral bioavailability is lower.

2

Time Administration

Inject fasted, typically first thing in the morning. Wait 30-60 minutes before eating. Fasting enhances fat mobilization effects.

3

Select Injection Site

Subcutaneous injection near abdominal fat stores is common, though systemic absorption means site selection may not critically matter.

4

Run Protocol Duration

Research protocols typically run 12-20 weeks. Fat metabolism effects are gradual and require consistent long-term use to assess.

5

Track Body Composition

Use DEXA scans or calipers at baseline and 8-12 week intervals. Body weight alone is insufficient—track fat mass specifically.

Warnings & Precautions

  • !Clinical trial results have been mixed—efficacy is not firmly established.
  • !Not FDA-approved for any indication.
  • !Effects are modest compared to GLP-1 agonists for weight loss.
  • !Ensure product authenticity, as this is a commonly counterfeited peptide.

Frequently Asked Questions

How does AOD-9604 differ from growth hormone?

AOD-9604 is the fat-metabolizing fragment (aa 177-191) of GH without the growth-promoting or insulin-resistant effects. It selectively targets lipolysis pathways.

Is AOD-9604 effective for weight loss?

Clinical trials showed modest fat reduction. It is significantly less effective than GLP-1 agonists like semaglutide. Results vary and the evidence base is limited.

Can AOD-9604 be taken orally?

Oral formulations exist (TGA-approved in Australia at 1 mg), but oral bioavailability is lower than injectable. Most research protocols use subcutaneous injection.

Related Protocols

Disclaimer: Protocol information is for educational purposes only. Not medical advice. Consult healthcare professionals.